



NDA 021958/S-002

SUPPLEMENT APPROVAL

Novartis Consumer Health
Attention: Karen Costa-Strachan, Ph.D.
Associate Director, Regulatory Affairs
200 Kimball Drive
Parsippany, NJ 07054-0622

Dear Dr. Costa-Strachan:

Please refer to your supplemental new drug application dated July 2, 2009, received July 6, 2009, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FDCA) for Lamisil AT (1 % terbinafine) Gel.

We acknowledge receipt of your submissions dated August 10, November 9, and 13, and December 24, 2009.

This "Prior Approval" supplemental new drug application provides for the addition of the "Relieves Itching, Burning, Cracking and Scaling," "Clinically Proven To Cure Most Athlete's Foot," "Advanced the only 7 dose, one a night, treatment for athlete's foot," and "Nighttime Therapy" statements, and a dermatophyte character to the Principal Display Panel for Lamisil AT Cream for athlete's foot.

We have completed our review of this application, as amended. It is approved, effective on the date of this letter, for use as recommended in the agreed-upon labeling text.

LABELING

Submit final printed labeling as soon as they are available, but no more than 30 days after they are printed. The final printed labeling (FPL) must be identical to the enclosed labeling (Lamisil AT Gel for athlete's foot 12-gram carton and immediate container labels submitted December 24, 2009), and must be in the "Drug Facts" format (21 CFR 201.66), where applicable.

The final printed labeling should be submitted electronically according to the guidance for industry titled *Providing Regulatory Submissions in Electronic Format – Human Pharmaceutical Product Applications and Related Submissions Using the eCTD Specifications (October 2005)*. Alternatively, you may submit 12 paper copies, with 6 of the copies individually mounted on heavy-weight paper or similar material. For administrative purposes, designate this submission "**Final Printed Labeling for approved NDA 021958/S-002.**" Approval of this submission by FDA is not required before the labeling is used.

We remind you that the banner “Advanced the only 7 dose, one a night, treatment for athlete’s foot,” is relative to the currently available therapies in the over-the-counter (OTC) market and may need to be revised or removed should other athlete’s foot products that are considered by the FDA to be equivalent or superior to Lamisil AT Gel enter the OTC market. We refer you to the July 24, 2006 FDA approval letter.

LETTERS TO HEALTH CARE PROFESSIONALS

If you issue a letter communicating important safety related information about this drug product (i.e., a “Dear Health Care Professional” letter), we request that you submit an electronic copy of the letter to both this NDA and to the following address:

MedWatch
Food and Drug Administration
5600 Fishers Lane, Room 12B05
Rockville, MD 20857

REPORTING REQUIREMENTS

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, call Neel Patel, Regulatory Project Manager, at (301) 796-0970.

Sincerely,

{See appended electronic signature page}

Joel Schiffenbauer, MD
Deputy Director
Division of Nonprescription Clinical Evaluation
Office of Nonprescription Products
Center for Drug Evaluation and Research

Enclosure: Labeling

Application
Type/Number

Submission
Type/Number

Submitter Name

Product Name

NDA-21958

SUPPL-2

NOVARTIS
CONSUMER
HEALTH INC

LAMISIL DERMGEL

This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

JOEL SCHIFFENBAUER
01/06/2010